Key Takeaways:
Ligand Pharmaceuticals priced $625 million of zero-coupon convertible senior notes due 2031 in a private placement, using part of the proceeds to repurchase shares and hedge against dilution.
"The notes will be general unsecured, senior obligations of Ligand and will not bear regular interest," the company said in a statement Wednesday.
Net proceeds are estimated at $605.3 million, or $678.2 million if initial purchasers exercise their option to buy an additional $75 million in notes within 13 days. Ligand plans to use about $72.9 million for convertible note hedge transactions and roughly $60 million to repurchase 228,859 shares at $262.17 apiece, matching the stock's last reported price on June 22. The remaining funds will support general corporate purposes, including its previously announced acquisition of Xoma Royalty Corp.
The notes convert at 2.9916 shares per $1,000 principal, equivalent to a conversion price of about $334.27 per share — a 27.5% premium to Monday's closing price. Ligand also entered warrant transactions with a strike price of $524.34 per share, or 100% above the same closing level. The convertible note hedges are designed to reduce potential dilution upon conversion, while the warrants could have a dilutive effect if Ligand's stock exceeds the strike price.
Ligand may not redeem the notes before September 21, 2029. Holders can require repurchase at 100% of principal plus accrued interest if the company undergoes a fundamental change. The notes mature on September 15, 2031.
The offering strengthens Ligand's balance sheet as it pursues its royalty aggregation strategy. Investors will watch for the closing of the Xoma Royalty deal and whether the company deploys additional capital toward further acquisitions.
This article is for informational purposes only and does not constitute investment advice.
